HLS Share Price Performance
AU$0
-1.42 (-100.00%)
Price AU$0
Fair ValueAU$0.90
Share Pricen/a
Healius Limited (ASX:HLS) Looks Inexpensive But Perhaps Not Attractive Enough
Jan 12
Healius Limited Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 30 Fair Values set on narratives written by author
HLS Community Narratives
AN
Fair Value AU$0.9 4.7% overvalued intrinsic discount
Digital Automation And Genomics Expansion Will Support A Stronger Long Term Pathology Business
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value AU$0.6 57.5% overvalued intrinsic discount
Digital And Labor Pressures Will Limit Pathology Margins And Earnings Recovery
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value AU$1.47 35.9% undervalued intrinsic discount
Genomic And Specialist Diagnostics Expansion Will Support A Stronger Long Term Outlook
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Genomic And Specialist Diagnostics Expansion Will Support A Stronger Long Term Outlook
Catalysts About Healius Healius operates a large-scale pathology and diagnostic services business focused on laboratory testing, collection centers and specialist diagnostics across Australia. What are the underlying business or industry changes driving this perspective?Read more
0
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
AU$1.47
35.9% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
5.95% p.a.
Profit Margin
4.63%
Future PE
17.89x
Price in 2029
AU$1.82
Digital And Labor Pressures Will Limit Pathology Margins And Earnings Recovery
Catalysts About Healius Healius operates a large-scale pathology and diagnostics network focused on laboratory testing and associated services across Australia. What are the underlying business or industry changes driving this perspective?Read more
26
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
AU$0.6
57.5% overvalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
4.3% p.a.
Profit Margin
1.99%
Future PE
17.73x
Price in 2028
AU$0.74
Digital Automation And Genomics Expansion Will Support A Stronger Long Term Pathology Business
Catalysts About Healius Healius is an Australian healthcare company focused on pathology and specialty diagnostics services, including genomics and clinical trials support. What are the underlying business or industry changes driving this perspective?Read more
19
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
AU$0.9
4.7% overvalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
4.44% p.a.
Profit Margin
0.026%
Future PE
20.09x
Price in 2028
AU$0.01
Trending Discussion
Recently Updated Narratives
AN
Genomic And Specialist Diagnostics Expansion Will Support A Stronger Long Term Outlook
Fair Value: AU$1.47 35.9% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Digital And Labor Pressures Will Limit Pathology Margins And Earnings Recovery
Fair Value: AU$0.6 57.5% overvalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Digital Automation And Genomics Expansion Will Support A Stronger Long Term Pathology Business
Fair Value: AU$0.9 4.7% overvalued intrinsic discount
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Healius Limited Key Details
About HLS
- Founded
- 1994
- Employees
- 5962
- CEO
- WebsiteView website
Healius Limited provides medical laboratory and pathology services in Australia. The company provides services under the Laverty Pathology, Dorevitch Pathology, QML Pathology, Western Diagnostic Pathology, Genomic Diagnostic, Vetnostics Pathology, QML Pathology, TML Pathology, Abbott Pathology, IQ Pathology, Kossard, Gastrolab, and Agilex Biolabs brands. It operates medical laboratories and patient collection centers. The company was formerly known as Primary Health Care Limited and changed its name to Healius Limited in December 2018. Healius Limited was incorporated in 1994 and is based in Sydney, Australia.
